Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

Wassihun Wedajo Aragaw, Christine Roubert, Evelyne Fontaine, Sophie Lagrange, Matthew D. Zimmerman, Véronique Dartois, Martin Gengenbacher, Thomas Dick

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.

Original languageEnglish (US)
Article numbere01400-21
JournalAntimicrobial agents and chemotherapy
Issue number1
StatePublished - Jan 2022

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


  • DnaN
  • Griselimycin
  • Mycobacterium abscessus
  • NTM
  • Nontuberculous mycobacteria


Dive into the research topics of 'Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice'. Together they form a unique fingerprint.

Cite this